Niagen Bioscience
NAGE
66 hedge funds and large institutions have $64.9M invested in Niagen Bioscience in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
56% more capital invested
Capital invested by funds: $41.6M → $64.9M (+$23.3M)
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
8% more funds holding
Funds holding: 61 → 66 (+5)
1.65% more ownership
Funds ownership: 21.36% → 23.01% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $80K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.03M |
| 2 |
BlackRock
New York
|
+$1.61M |
| 3 |
Renaissance Technologies
New York
|
+$941K |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$901K |
| 5 |
Two Sigma Investments
New York
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$2.01M |
| 2 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$367K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$196K |
| 4 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$112K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$90K |
NAGE Hedge Fund Activity: Q2 2020 in Review
66 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2020, worth a combined $64.9M — up 56% from $41.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NAGE positions and 5 closed out — a net gain of 6 holders — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.03M. The largest seller was Tieton Capital Management, cutting an estimated $2.01M.
- 66 institutional investors held Niagen Bioscience (NAGE) as of Q2 2020, up from 61 in Q1 2020.
- Funds reported $64.9M of Niagen Bioscience stock for Q2 2020, up 56% quarter-over-quarter.
- 11 funds opened new Niagen Bioscience positions in Q2 2020 and 5 closed out, a net change of +6 holders.
- The largest Niagen Bioscience buyer in Q2 2020 was Morgan Stanley, an estimated $2.03M added.
- The largest Niagen Bioscience seller in Q2 2020 was Tieton Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2020.